Trials explorer

AI-generated summary

Olaparib In Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1) +7 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed invasive breast cancer with stage IV disease, either biopsy proven or with unequivocal evidence of metastatic disease by physical examination…. Goal: This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Beth Israel Deaconess Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation +3 • Eligibility: Inclusion Criteria: 1. Provide written informed consent; 2. Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; 3. Has Eastern Cooperative Oncology…. Goal: The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Acerand Therapeutics (Shanghai) Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria 1. Histological or cytological proven adenocarcinoma of the pancreas. 2. Locally advanced unresectable or metastatic disease not amenable to curative treatment. 3. No prior treatment for…. Goal: Patients will be tested for mutations in the BRCA2 gene. If they have a BRCA2 mutation, they will be treated with Mitomycin-C as described here. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention is being studied. Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation +3 • Eligibility: Inclusion Criteria: * Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers. * Age at inclusion;…. Goal: The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Medical Center Nijmegen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Registry of Subjects at Risk of Pancreatic Cancer is being studied. Conditions: Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation +4 • Eligibility: Inclusion Criteria to enter the registry: * individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree * subjects…. Goal: IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Associazione Italiana per lo Studio del Pancreas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations is being studied. Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation +11 • Eligibility: Inclusion Criteria: 1. Women must be ≥ 30 and ≤ 50 years of age. 2. Premenopausal women with a documented deleterious mutation in one of the following ovarian…. Goal: This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care is being studied. Conditions: Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Male 2. Age 25 -70 3. At least one first-, or second--degree relative who has been found to carry a BRCA1 or BRCA2 mutation. Exclusion…. Goal: The primary goal of this research is to develop and test a web-based genetic education/counseling intervention. This intervention is designed to educate men from hereditary cancer families about the personal relevance of genetic testing in order to help them make decisions about whether to pursue genetic testing. Phase/Status/Sponsor: Unknown phase; COMPLETED; Georgetown University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction is being studied. Conditions: Breast Reconstruction, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2) +1 • Eligibility: Inclusion Criteria: * Women aged 18 years and older * Candidates who have already been selected to undergo nipple sparing mastectomy and immediate implant reconstruction by the breast…. Goal: This study is being carried out to better understand how different types of mastectomy surgeries affect women's recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction. There are different ways to perform a mastectomy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Beaumont Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members is being studied. Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation +8 • Eligibility: Inclusion Criteria: * PILOTS I, II AND III: Body mass index (BMI) of 25 or higher OR \< 150 minutes of moderate to vigorous exercise per week OR…. Goal: This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients, chronic lymphocytic leukemia (CLL) survivors or family members of cancer survivors who are at high risk for cancer. Increasing exercise and eating healthy foods may help reduce the risk of cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical…. Goal: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FTT PET/CT in Pancreatic Neuroendocrine Tumors is being studied. Conditions: Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors • Eligibility: Inclusion Criteria: 1. Patients must be ≥ 18 years of age. 2. Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic…. Goal: A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). Phase/Status/Sponsor: Unknown phase; RECRUITING; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blood Markers of Early Pancreas Cancer is being studied. Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst +3 • Eligibility: Inclusion Criteria: * Age ≥19 * Able to provide written, informed consent * Able to attend an in-person study visit in Omaha, NE twice a year to collect…. Goal: Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Nebraska.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Decision Support for BRCA Testing in Ethnically Diverse Women is being studied. Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation +1 • Eligibility: Inclusion Criteria (Patient Participants): * Women, age 21-75 years * Meets criteria for genetic testing based on family history * Sees a primary care provider in the Columbia…. Goal: The objective of this study is to expand genetic testing for hereditary breast and ovarian cancer syndrome to a broader population of high-risk women by prompting appropriate referrals from the primary care setting with the use of an electronic health record-embedded breast cancer risk navigation (BNAV) tool. To address patient-related barriers to genetic testing, the investigators developed a web-based decision aid, RealRisks, which is designed to improve genetic testing knowledge, accuracy of breast cancer risk perceptions, and self-efficacy to engage in a collaborative dialogue about genetic testing. Phase/Status/Sponsor: Unknown phase; COMPLETED; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion: * \>18 years of age * Histologically proven pancreatic ductal adenocarcinoma, poorly differentiated carcinoma, or adenosquamous carcinoma * Radiographic evidence of metastatic disease * At least 1…. Goal: A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. Phase/Status/Sponsor: Unknown phase; RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) is being studied. Conditions: Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein • Eligibility: Inclusion Criteria: * Confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists. Exclusion Criteria: * Anti-cancer therapy including chemotherapy,…. Goal: To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: * women from family with more than two breast cancer cases and one or more cases of ovarian cancer diagnosed at any age; * women from…. Goal: This study aimed to compare the activity of Thymidine Kinase 1 in serum of two groups of woman at high and normal risk for breast/ovary cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Hadassah Medical Organization.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pancreatic Cancer Screening for At-risk Individuals is being studied. Conditions: Pancreatic Cancer, Adult • Eligibility: Inclusion Criteria: * Inclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do…. Goal: The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beth Israel Deaconess Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quebec Pancreas Cancer Study is being studied. Conditions: Pancreas Cancer, Pancreatic Cancer, Pancreas Neoplasm +8 • Eligibility: Inclusion Criteria: * Individual diagnosed with pancreatic cancer. * Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer). * Individual diagnosed with…. Goal: The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families. Phase/Status/Sponsor: Unknown phase; RECRUITING; George Zogopoulos.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a combination therapy using a PARP inhibitor, PD-1 immunotherapy, and SBRT radiation for metastatic or advanced bone and soft tissue sarcoma. It is for people aged 10 to 70 with high-grade sarcoma that has spread or cannot be fully removed, who have had at least one prior systemic treatment and have not used a PARP inhibitor before. The study aims to see how well this combination works and how safe it is, and to explore tumor biomarkers to guide future personalized treatment. Exclusions include a second cancer within the last five years, active autoimmune disease requiring systemic therapy, prior anti-PD-1/PD-L1 therapy, HIV, pregnancy or breastfeeding, and recent live vaccines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cell-free DNA in Hereditary And High-Risk Malignancies 1 is being studied. Conditions: Hereditary Cancer Syndrome • Eligibility: Inclusion Criteria: 1. Individual with any known or suspected hereditary cancer predisposition (i.e. individuals with an identified pathogenic or likely pathogenic variant in a cancer predisposition gene and/or…. Goal: The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Ability to provide informed consent * Voluntary consent to participate * CanRisk score (without PRS) \> 5% (calculated on www.canrisk.org) * Healthy women with: 1.…. Goal: The goal of this single-arm interventional study is to learn whether integrating a polygenic risk score (PRS) into the CanRisk model can help improve breast cancer risk prediction and prevention in adult women with or without a family history of breast cancer and in women diagnosed with unilateral breast cancer. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Boccia Stefania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial is being studied. Conditions: BRCA Mutation, Estrogen Deficiency, Surgical Menopause +3 • Eligibility: Inclusion Criteria: * Women between 18-40 years old; * BRCA1/2 germline mutations; * Completed childbearing; * Willing to undergo RRSO; * Negative final histological examination; * No previous…. Goal: Selecting theca and granulosa cells from removed ovaries of BRCA1/2mut patients undergoing Risk-reducing salpingo-oophorectomy (RRSO) and developing a 3D bioprinted hormone-producing bioprosthetic model. If efficacy and tolerability are confirmed in vivo, this bioprosthetic model might be used to replace hormones' production in BRCA mutated patients undergoing prophylactic surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting is being studied. Conditions: Prostatic Neoplasms • Eligibility: Inclusion Criteria: * Age \> 20, Japanese men at the time of informed consent. * Patients who provided informed consent. If the patient has died, opt-out will be…. Goal: The purpose of this study is to investigate the prevalence of tissue homologous recombination repair (HRR)-related gene mutations (positive/negative/Variant of uncertain significance (VUS)), clinical outcome such as prostate-specific antigen-progression free survival (PSA-PFS), overall survivals (OS) and treatment pattern in mCRPC patients. \<Methods\> Study design: multi-center, prospective cohort study Data Source(s): In this study, 155 patients (expected recruitment patients: maximum 205 patients) will be enrolled from approximately 20\~30 sites in Japan. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is being studied. Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer +7 • Eligibility: Inclusion Criteria: 1. Adults 18 years old or older. 2. Newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease. 3.…. Goal: Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CanariaBio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes is being studied. Conditions: Solid Tumor • Eligibility: Key Inclusion Criteria: * Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease * Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate…. Goal: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes. Phase/Status/Sponsor: Unknown phase; TERMINATED; pharmaand GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Patients with primary ovarian cancer, fallopian tube cancer, or peritoneal cancer confirmed by histology. 2. Patients who are taking niraparib. 3. Age greater than or…. Goal: Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Phase/Status/Sponsor: Unknown phase; UNKNOWN; First Affiliated Hospital Xi'an Jiaotong University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Undergoing medical care at UVA * Up to date breast cancer screening * Subjects must fall into one of the following groups: * Women at…. Goal: The purpose of this study is to create new tests to identify biomarkers for ovarian cancer so that a screening test can be developed. For patients who have a diagnosis of ovarian Cancer, researchers will use blood samples before and after treatment to see if disease status can be determined by measuring the amount of biomarker. Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Virginia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Development of Human Immunologic Assays Specific to Folate Receptor Antigen is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Ovarian cancer patients. Goal: Ovarian cancer has the highest mortality rate of gynecologic malignancies and the overall 5-year survival rate of ovarian cancer is only 20-30%. Additionally, the incidence of ovarian cancer has increased in recent years in Taiwan. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National Taiwan University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SC10914 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Signed written informed consent * Aged 18-70 years * Dose escalation study: Subjects diagnosed with advanced solid malignancies who are refractory to standard therapies or…. Goal: SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Jiangxi Qingfeng Pharmaceutical Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer is being studied. Conditions: Fallopian Tube Cancer • Eligibility: Inclusion Criteria: * Patients ≥18 years of age or adults according to age of majority as defined by the local regulations; * Willing and able to provide written…. Goal: To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer. Presently, the prevalence data for HRD are available from selected geographies only and range from 31% to 50%. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested niraparib, a PARP inhibitor, in adults whose tumors have BAP1 or other DNA damage repair (DDR) gene mutations. - It was open-label and non-randomized, sponsored by the University of Florida, to see if niraparib can shrink DDR-deficient cancers. - Eligible participants included adults with incurable cancers such as uveal melanoma, mesothelioma, clear cell renal cell carcinoma, or cholangiocarcinoma (cohort A) with a confirmed DDR mutation (with a separate cohort for additional DDR criteria). - Exclusions included prior PARP inhibitor therapy and known BRCA1/2 mutations; the trial has been completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study is being studied. Conditions: Breast Cancer • Eligibility: * ELIGIBILITY CRITERIA: Inclusion Criteria - Menstrual Cycle Study: To participate in the Menstrual Cycle Pilot Study, a woman must: Must be at least 25 years of age…. Goal: Women who carrying a BRCA1 or BRCA2 gene mutation or who are the first- or second-degree relative of an individual with a BRCA-associated cancer in a family documented to have a BRCA1 or BRCA2 mutation will be eligible for enrollment into this pilot study of breast cancer screening modalities. We will recruit up to fifty women (twenty-five women who carry an altered BRCA1 or BRCA2 gene and 25 non-carriers matched by age and family mutation type) with regular menstrual cycling (documented by menstrual history and premenopausal FSH level). Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ovarian Screening Study is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Asymptomatic women over the age of 45 with one or both ovaries. * Women over the age of 25 with one or both ovaries and…. Goal: The objectives of this study are: * To identify women at increased risk for developing ovarian cancer * To detect ovarian cancers at an early stage * To investigate the role of tumor membrane fragments as tumor markers for early ovarian carcinoma Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Louisville.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma is being studied. Conditions: Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) or aggressive lymphoma (diffuse…. Goal: The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab. We will also study how safely this combination of medication can be given in advanced cancer and lymphoma and benefits of receiving this therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Northwestern University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations is being studied. Conditions: Gastrointestinal Malignancies • Eligibility: Inclusion Criteria: * Voluntary written informed consent form (ICF) of the patient obtained before any study-specific procedure. * Age ≥ 18 years of age; male or female. *…. Goal: The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations. Phase/Status/Sponsor: Unknown phase; COMPLETED; HonorHealth Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer, Advanced Cancer • Eligibility: Inclusion criteria: 1. Histological or cytological proof of advanced cancer pre-treated with maximally one line of systemic chemotherapy in the advanced setting and any line of hormonal therapy…. Goal: A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib. Phase/Status/Sponsor: Unknown phase; COMPLETED; The Netherlands Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Diagnosis of invasive breast cancer or DCIS * Appropriate for genetic testing, defined as if they meeting one or more of the following criteria (note…. Goal: Genes are the "blueprints" for our bodies. Some people are born with an abnormal copy ("mutation") of a gene. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) is being studied. Conditions: Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma +2 • Eligibility: Inclusion Criteria: * Males or females ≥ 18 years old (Parts 1 and 2A); males or females ≥ 12 years old and with a body weight ≥ 40…. Goal: Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL). Phase/Status/Sponsor: Unknown phase; TERMINATED; Kronos Bio.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans is being studied. Conditions: Ovarian Neoplasm, Cancer Genetics, Breast Cancer • Eligibility: * INCLUSION CRITERIA: Understands and speaks English African American Women 18 years or older Has had genetic testing for BRCA1/2 mutations. Goal: Background: \- Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Human Genome Research Institute (NHGRI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested whether bile samples can reveal the tumor mutation profile and genotype in people with malignant biliary strictures (cholangiocarcinoma or cancer of the head of the pancreas). It also looked at whether levels of VEGF and MMPs in bile could help diagnose these conditions. For tumor genotyping, 10 adults who were surgically treated for malignant biliary stricture with confirmed cancer were included; for biomarkers, bile collected during ERCP from 100 adults (50 malignant, 50 benign) was analyzed. Eligible participants were adults who consented to storage of bile and tissue in the hospital tissue bank; those who did not consent were excluded. The trial is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a phase I trial testing veliparib together with cisplatin and gemcitabine for adults with advanced biliary tract cancer, pancreatic cancer, urothelial cancer, or non-small cell lung cancer. The study aims to find the highest dose of veliparib that can be given safely with these drugs and to identify the recommended dose for future studies. It will also assess anti-tumor activity and collect blood and tumor samples to study pharmacokinetics and BRCA-related biomarkers. Eligibility includes no prior systemic therapy, adequate organ function, no CNS metastases, not pregnant, and participants are stratified by BRCA mutation status.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer is being studied. Conditions: Prostate Cancer, Castration-resistant Prostate Cancer • Eligibility: Inclusion Criteria: * Have metastatic castration-resistant prostate cancer (prostate cancer progressing by PSA (rise by 25% on prior therapy) or imaging despite castrate levels of testosterone \[\<50 ng/dL\]…. Goal: This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair gene mutations (DDRm). In brief, the primary endpoint is PSA50 response , defined by a 50% reduction in PSA from baseline . Phase/Status/Sponsor: Unknown phase; TERMINATED; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer is being studied. Conditions: High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8 +7 • Eligibility: Inclusion Criteria: * With suspected advanced ovarian cancer or genetic predisposition to malignant neoplasm of the ovary * Planned surgery * Have a uterus and no history of…. Goal: The goal of this project is to develop a minimally invasive test to detect ovarian cancer, by searching for mutations from the tumor in samples obtained from the cervix (Pap smears), and from the uterus (uterine lavage) in participants with advanced ovarian cancer and in participants with increased risk of ovarian cancer due to inherited mutations, such as BRCA or BRCA2 (among others). Pap smear and uterine lavage samples will be collected while the participant is under anesthesia for planned debulking surgery. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Washington.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study anonymously screens archived tissue samples from Ashkenazi Jewish individuals with cancer to test for three common BRCA founder mutations (in BRCA1/BRCA2). - Participants are people who self-identify as Jewish and have cancer, with a tumor block or DNA available for testing at MSKCC or collaborating centers. - The goal is to find out how common these mutations are in this group and whether carriers may have a higher risk of cancers beyond breast and ovarian cancer. - Researchers will analyze results by cancer type and use the findings to identify people who might benefit from genetic counseling or testing and to inform high-risk screening or preventive options.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has recurred following a platinum-based regimen used at initial diagnosis * Measurable disease * Estimated life…. Goal: This research study is a way of gaining new knowledge about a drug called olaparib in women who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1) or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with the exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from repairing their DNA. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) is being studied. Conditions: Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma +1 • Eligibility: Inclusion Criteria Phase 1b (all arms): * Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR…. Goal: This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific participant populations in an expansion phase (Phase 2 cohorts). Phase/Status/Sponsor: Unknown phase; TERMINATED; pharmaand GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma is being studied. Conditions: HRD, Cholangiocarcinoma, Metastatic Cancer • Eligibility: Inclusion Criteria: Subject must meet all of the following applicable inclusion criteria to participate in this study: * Written informed consent and HIPAA authorization for release of personal…. Goal: Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Walid Shaib, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.